FDA warning letter to Genogenix over unapproved GLP-1 peptides

The Food and Drug Administration issued a warning letter dated January 20, 2026, to GenoGenix LLC of Boca Raton, Florida, saying the company's compounded drug products failed to meet federal requirements for outsourcing facilities and put patients at risk ^[1]. GenoGenix had registered with the FDA as a 503B outsourcing facility in February 2025, a status that allows certain sterile compounding without full drug approval, but only if strict conditions are met ^[1].

FDA investigators inspected the facility from July 14 to July 18, 2025, and issued an initial inspection report the same week, followed by an amended report on July 31, 2025 ^[1]. The agency reviewed the company's responses from August, September, October, and November 2025 ^[1]. By the time the letter was issued, GenoGenix had already stopped producing and distributing drugs, and it had started a voluntary recall on July 30, 2025, of sterile products that were within their expiration dates but lacked assurance of sterility or showed possible microbial contamination ^[1].

The letter says GenoGenix compounded drugs using ingredients not permitted for outsourcing facilities, including 5-amino-1-methylquinolinium iodide (5-Amino-1MQ) and nicotinamide adenine dinucleotide (NAD+), neither of which appears on the FDA's approved list of bulk substances for this kind of compounding ^[1]. Products named in the letter — including Glutathione Magnesium, Reconstitution Solution, Epithalon, Rapamycin, Clear Mind 150, and Alpha Lipoic Acid — were missing required labeling such as a statement that the drug is compounded, the facility's name and address, ingredient lists, dosage form, and storage instructions ^[1]. Some containers also lacked directions for use and contact information for reporting adverse events ^[1].

Inspectors also documented sterility problems inside the production areas: workers reportedly blocked protective airflow with gloved hands, touched sterile surfaces directly, and worked without ever conducting the standard tests — called media fills — used to confirm that sterile production is reliable ^[1]. The letter states the facility never performed personnel or environmental monitoring during drug production and never validated the equipment used to sterilize products ^[1]. Investigators also flagged design issues in the cleanroom, including HEPA filters positioned in a way that may prevent proper air circulation and visible gaps in cleanroom doors that could let in lower-quality air ^[1]. GenoGenix also failed to file required biannual reports on the drugs it compounded and had no documented process for reporting adverse events to the FDA ^[1].

The text of the letter reviewed here does not itself name tirzepatide or other GLP-1 peptide products among the specific compounded items listed; whether GLP-1-related peptides were among the drugs made at this facility is not established in the letter ^[1].

Why it matters for patients

People who buy compounded or research-labeled peptides outside the regular pharmacy and prescription system have no guarantee the product was made under the sterility and labeling controls the FDA requires of outsourcing facilities ^[1]. This letter shows what can go wrong even at a facility that had registered with the FDA: missing sterility testing, missing ingredient disclosures, and a recall tied to contamination risk ^[1]. Patients relying on such products may not know the exact ingredients, concentrations, or handling instructions, which the letter says were absent from several product labels ^[1].

What happens next

The letter does not state what additional FDA action, if any, will follow, or set a timeline for further review of GenoGenix's practices ^[1]. The company had already ceased drug production and distribution and completed a recall of sterile products by the time the letter was issued ^[1].